Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6691509 | 0.90 | THRB (0.52) | THRBKMT2ACNR2DNMT3AAKR1C3 | |
| SCHEMBL6693323 | 0.83 | THRB (0.61) | THRBKMT2ANPC1RAB9ATHRA | |
| SCHEMBL6689854 | 0.82 | L3MBTL1 (0.39) | THRBKMT2ALMNASMN1; SMN2 | |
| SCHEMBL6692440 | 0.80 | THRB (0.36) | THRBKMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL6690382 | 0.79 | THRB (0.60) | THRBKMT2ANPC1RAB9ATHRA | |
| SCHEMBL6689993 | 0.78 | RORC (0.48) | THRBTHRA | |
| SCHEMBL6690029 | 0.77 | THRB (0.43) | THRBTHRA | |
| SCHEMBL7262915 | 0.74 | AKR1C3 (0.51) | KMT2ADNMT3AAKR1C3MAPTNPC1 | |
| SCHEMBL6690024 | 0.72 | SMN1; SMN2 (0.48) | KMT2ALMNATP53SMN1; SMN2 | |
| SCHEMBL3784241 | 0.71 | DNMT3A (0.80) | DNMT3ALMNANPC1RAB9AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747048-B2 | TREATING DISEASES OR DISORDERS ASSOCIATED WITH METABOLISM DYSFUNCTION OR WHICH ARE DEPENDENT UPON THE EXPRESSION OF A T3 REGULATED GENE, | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-08 | — | — | US | disclosed |
| US-20040039028-A1 | Pyridine-based thyroid receptor ligands | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039028-A1 | Pyridine-based thyroid receptor ligands | TSHR, THRB, THRA | THRB 2/4885KMT2A 2819/4885CNR2 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.